Page 46 - Read Online

Page 68 Olivera et al. Cancer Drug Resist 2019;2:53-68 I http://dx.doi.org/10.20517/cdr.2018.25

65. Scully RE, Lipshultz SE. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovascular Toxicology
2007;7:122-8.
66. Minotti G. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol
Rev 2004;56:185-229.
67. Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 2007;7:56-60.
68. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, et al. A coding variant in RARG confers susceptibility to anthracycline-
induced cardiotoxicity in childhood cancer. Nat Genet 2015;47:1079-84.
69. Aminkeng F, Ross CJD, Rassekh SR, Hwang S, Rieder MJ, et al. Recommendations for genetic testing to reduce the incidence of
anthracycline-induced cardiotoxicity. Br J Clin Pharmacol 2016;82:683-95.
70. Visscher H, Ross CJD, Rassekh SR, Sandor GSS, Caron HN, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers
predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 2013;60:1375-81.
71. Ryerson AB, Border WL, Wasilewski-Masker K, Goodman M, Meacham L, et al. Assessing anthracycline-treated childhood cancer
survivors with advanced stress echocardiography. Pediatr Blood Cancer 2015;62:502-8.
72. Tuzovic M, Wu PT, Kianmahd S, Nguyen KL. Natural history of myocardial deformation in children, adolescents, and young adults
exposed to anthracyclines: systematic review and meta-analysis. Echocardiography 2018;35:922-34.
73. Rose-Felker K, Border WL, Hong BJ, Chow EJ. Cardio-oncology related to heart failure: pediatric considerations for cardiac
dysfunction. Heart Failure Clinics 2017;13:311-25.
74. Kaudle KE, Keeling NJ, Klein TE, Whirl-Carrillo M, Pratt VM, et al. Standardization can accelerate the adoption of pharmacogenomics:
current status and the path forward. Pharmacogenomics 2018;19:847-60.